Shionogi-ViiV Healthcare announces initial data from pivotal phase III study of dolutegravir in HIV
ViiV Healthcare and Shionogi & Co., Ltd. today announced that initial results have been received from the SPRING-2 (ING113086) Phase III study of the investigational integrase inhibitor dolutegravir in treatment-naïve adults with HIV-1. The study met its primary objective, demonstrating non-inferiority of dolutegravir to raltegravir.
- (1888PressRelease) April 02, 2012 - Through 48 weeks, 88% of study participants on dolutegravir were virologically suppressed (
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam